These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 23571835)
1. Prednisone: the last gasp of immunosuppresive therapy for restenosis prevention. Waksman R; Epstein SE Eur Heart J; 2013 Jun; 34(23):1702-4. PubMed ID: 23571835 [No Abstract] [Full Text] [Related]
2. Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA-DES). Ribichini F; Tomai F; Pesarini G; Zivelonghi C; Rognoni A; De Luca G; Boccuzzi G; Presbitero P; Ferrero V; Ghini AS; Marino P; Vassanelli C; Eur Heart J; 2013 Jun; 34(23):1740-8. PubMed ID: 23492671 [TBL] [Abstract][Full Text] [Related]
3. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale. Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384 [TBL] [Abstract][Full Text] [Related]
7. Is a Drug-Eluting Stent the Default Treatment Strategy for Drug-Eluting Stent Restenosis? Colombo A; Ruparelia N J Am Coll Cardiol; 2015 Jul; 66(1):34-6. PubMed ID: 26139055 [No Abstract] [Full Text] [Related]
8. Towards defining the role of drug eluting stents. Tarantini G; Ramondo A; Razzolini R Minerva Cardioangiol; 2008 Feb; 56(1):29-34. PubMed ID: 18432166 [No Abstract] [Full Text] [Related]
9. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. Ardissino D; Cavallini C; Bramucci E; Indolfi C; Marzocchi A; Manari A; Angeloni G; Carosio G; Bonizzoni E; Colusso S; Repetto M; Merlini PA; JAMA; 2004 Dec; 292(22):2727-34. PubMed ID: 15585732 [TBL] [Abstract][Full Text] [Related]
10. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis. El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402 [TBL] [Abstract][Full Text] [Related]
11. Choice of drug-eluting stents. Med Lett Drugs Ther; 2012 Dec; 54(1406):102-3. PubMed ID: 23282791 [No Abstract] [Full Text] [Related]
12. Systemic rapamycin to prevent restenosis: a glimpse to the past? Belardi J Catheter Cardiovasc Interv; 2010 Feb; 75(3):326. PubMed ID: 20162697 [No Abstract] [Full Text] [Related]
13. Recurrent restenosis after implantation of sirolimus-eluting stents in aorto-ostial lesions: successful treatment with polytetrafluoroethylene-covered stents. Gagnor A; Varbella F; Rubartelli P; Luceri S; Conte MR J Cardiovasc Med (Hagerstown); 2008 Feb; 9(2):201-4. PubMed ID: 18192816 [TBL] [Abstract][Full Text] [Related]
14. Could Paclitaxel-eluting stents be superior to sirolimus-eluting stents for the treatment of saphenous vein graft lesions? Brilakis ES; Banerjee S Am J Cardiol; 2010 Nov; 106(9):1367-8. PubMed ID: 21029842 [No Abstract] [Full Text] [Related]
15. Drug-eluting stents for secondary prevention of restenosis. Kastrati A Catheter Cardiovasc Interv; 2004 Nov; 63(3):265-6. PubMed ID: 15505858 [No Abstract] [Full Text] [Related]
16. Initial and late efficacy of everolimus-eluting stents for small and non-small coronary lesions from evaluating delayed late loss study. Tama N; Uzui H; Horita Y; Namura M; Tada H Heart Vessels; 2017 Dec; 32(12):1415-1423. PubMed ID: 28687988 [TBL] [Abstract][Full Text] [Related]
18. Drug-eluting stents: a new treatment in the prevention of restenosis. Part II: Clinical studies. Salu KJ; Bosmans JM; Bult H; Vrints CJ Acta Cardiol; 2004 Apr; 59(2):165-77 contd. PubMed ID: 15139658 [No Abstract] [Full Text] [Related]
19. Choosing a drug-eluting stent: how are CYPHER and TAXUS different? Perin EC J Invasive Cardiol; 2004 Sep; 16 Suppl F():12F-16F; discussion 18F-21F. PubMed ID: 23573648 [No Abstract] [Full Text] [Related]